Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX? (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible
After nearly five years of follow-up, median progression-free survival was not reached, and a significant overall survival benefit was observed; data will be presented as a late-breaking abstract at the
United States United Kingdom Bortezomib Melphalan Noah Reymond Jennifer Mcintyre Christopher Delorefice
Source: finanznachrichten.de